Compare Nuwellis Inc (NUWE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Organon & Co. Common Stock — how do they compare? Nuwellis Inc trades at $0.55 (market cap $2.00M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 1810× Nuwellis Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 27 Days and Organon & Co. Common Stock for 0 Days on average.
| NUWE | OGN | |
|---|---|---|
Market Cap | $2.00M | $3.62B |
Volume | 172,259 | 2,892,999 |
Sector | Health | Health |
52-Week High | $146.65 | $13.81 |
52-Week Low | $0.53 | $5.70 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | -$1.72M | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.621, down 7.35% today, with a bearish technical signal despite oversold RSI readings. The company shows revenue growth with 2026 revenue reaching $9M, but continues to post significant losses with a -125.63% net income margin. Recent positive developments include strong Aquadex console adoption and expanded pediatric footprint, though cash flow remains negative requiring ongoing financing.
The outlook remains challenging with persistent losses and negative cash flow offset by promising commercial momentum. Investment opportunity hinges on the company's ability to achieve profitability while risks include execution challenges and dependence on financing. Analyst sentiment is mixed with equal buy/hold ratings reflecting the high-risk, high-reward nature of this medical technology stock.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
